GSK4527226
2 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
2
Ongoing
2
Recruiting
1
Completed
0
Sites
92
Countries
16
Endpoints
16
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 16 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 12 of 16 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
5
3
2
1
1
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
2 of 2
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| PROGRESS-ADEfficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease | GSK4527226 Alzheimer’s disease | MCI due to AD / mild AD dementia | Ph 2 | Active, not recruiting | 97 | Sep 2026 | - | |
| NCT07105709Open-label Extension Study in Participants With Early Alzheimer's Disease | GSK4527226 Alzheimer’s disease | Age 50-85 | Ph 2 | Recruiting | 33 | Sep 2028 | - |
Showing 1-2 of 2 trials